source
- Mid-dose petrelintide shows strongest weight loss in phase-2 trial, paving way for pivotal studyRoche and Zealand Pharma released new phase-2 data for petrelintide, an amylin analog being developed for obesity treatment. In the Zupreme 1 trial, the 5 mg dose achieved the greatest mean weight…
- Atara and Pierre Fabre resubmit Ebvallo cell therapy after second FDA rejectionAtara Biotherapeutics and Pierre Fabre Pharmaceuticals have filed a new FDA submission for their cell therapy candidate Ebvallo (tabelecleucel), aimed at treating Epstein‑Barr virus‑positive post‑t…